<DOC>
	<DOCNO>NCT00124124</DOCNO>
	<brief_summary>In study , melanoma vaccine ( 5 melanoma peptide ) give either Montanide dendritic cell adjuvant . This randomized trial establish safety vaccine compare 2 vaccine adjuvant efficacy induce immune response .</brief_summary>
	<brief_title>Comparison Dendritic Cells Versus Montanide Adjuvants Melanoma Vaccine</brief_title>
	<detailed_description>In study , examine whether DCs pulse candidate melanoma-specific peptide KLH boost CTL responses melanoma antigen melanoma patient clinically free disease high risk recurrence . This vaccine compare direct injection peptide KLH Montanide adjuvant .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Resected stage IIB , IIC , stage III melanoma . Fully recover surgery Human leukocyte antigen ( HLA ) A*0201 positive . Age &gt; 18 year . Karnofsky performance status : &gt; 80 % normal lab . Prior chemotherapy . Known chronic infection HIV , hepatitis B C. Patients know autoimmune disease [ e.g . systemic lupus erythematosus ( SLE ) , rheumatoid arthritis ( RA ) ] . Patients vitiligo exclude . Pregnant woman . Patients know allergy gentamicin , tobramycin , streptomycin amikacin ( risk crossreaction aminoglycosides ) . Patients know retinal choroidal eye disease . Patients previously treat one peptide use trial , melanoma protein vaccine , melanoma whole cell vaccine , Montanide eligible . Allergy shellfish .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>